Glipizide, a new sulfonylurea in the treatment of diabetes mellitus. Summary of clinical experience in 1064 cases.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006029:Glycosuria / Q000188:drug therapy; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011517:Prothrombin Time; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D014839:Vomiting / Q000139:chemically induced
D001786:Blood Glucose; D001798:Blood Proteins; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D002784:Cholesterol; D014044:Tolbutamide; D000637:Transaminases